Introduction The lifetime risk for depression is greater in women than men ( ) and is especially high during female reproductive events including the perimenstrual, peripartum, and perimenopausal phases. The…
Scope of problem Major Depressive Disorder (MDD) is a common, often recurrent or chronic illness associated with significant morbidity. According to the World Health Organization, an estimated 4.4% of the…
Introduction According to the World Health Organization (WHO), bipolar or unipolar depression is the leading cause of ill health and disability worldwide. Depression affects nearly 20% of the population with…
Medications targeting the hypothalamic–pituitary–adrenal (HPA) axis Dysfunction in the hypothalamic–pituitary–adrenal (HPA) axis is one of the most well-established biological alterations in psychiatry ( ). The first observations of an elevation…
Acknowledgment Special thanks to Britt Gott, MS, for her editorial input and assistance with the compilation of this chapter. Introduction Fortunately, most individuals who suffer from major depressive disorder (MDD)…
Introduction The management of suicide risk is often integral to the care of people with treatment-resistant depression (TRD). Suicide is a major public health concern worldwide, and yet it is…
Thus far, this text has focused on the understanding and application of a broad range of interventions to improve outcomes in treatment-resistant depression. Understanding the breadth of psychopharmacologic and psychotherapeutic…
Among the many challenges of treating depression are the complications that arise when the depression is concurrent with other medical conditions. Not surprisingly, when a patient has two conditions, insufficient…
Personality disorders are some of the most common comorbid psychiatric conditions in major depressive disorder (MDD). The combination of MDD and personality disorders provides a real challenge to clinicians, as…
Introduction Treatment-resistant depression in children and adolescents is defined as clinically significant depression that has not responded to treatment with a selective serotonin reuptake (SSRI) for at least 8 weeks…
